Upload
others
View
9
Download
0
Embed Size (px)
Citation preview
235 (1 – A )
D ±ÜÅÍæ°±ÜâÔ¤Pæ¿á®Üá° ñæÃæ¿ááÊÜíñæ ¯ÊÜáWæ £ÚÓÜáÊÜÊÜÃæWÜã C¨Ü®Üá° ñæÃæ¿áPÜãvÜ Üá
±ÜÅÍæ° ±ÜâÔ¤Pæ ÍæÅà~
±ÜÅÍæ° ±ÜâÔ¤Pæ
¯©ìÐÜr ±Ü£ÅPæ (±Ü£ÅPæ II)
ÓÜÊÜá¿á : 2 WÜípæWÜÙÜá WÜÄÐÜu AíPÜWÜÙÜá : 200
ÓÜãaÜ®æWÜÙÜá 1. ±ÜÄàûæ ±ÝÅÃÜí»ÜWæãívÜ ñÜûÜ|Êæà J.Gí.BÃ…. EñܤÃÜÖÝÙæ¿áÈÉ ±ÜÅÍæ° ±ÜâÔ¤Pæ ÍæÅà~¿á®Üá° WÜáÃÜáñÜá ÊÜÞvÜáÊÜ Êæã¨ÜÆá, D ±ÜÅÍæ° ±ÜâÔ¤Pæ¿áÈÉ
ÊÜáá©ÅñÜÊÝWÜ Ü A¥ÜÊÝ ÖÜÄ©ÃÜáÊÜ A¥ÜÊÝ ¿ÞÊÜâ æà ±Üâo CÆÉ©ÃÜáÊÜ A¥ÜÊÝ ÊÜáá©ÅñÜÊÝWÜ Ü ±ÜÅÍæ°WÜÙÜá CñÝ© JÙÜWæãíwÆÉÊæíŸá¨Ü®Üá° ¯àÊÜâ ±ÜÄàüÓÜñÜPÜR Üáª. Êæáà騆 ¿ÞÊÜâ æà ¨æãàÐÜ PÜívÜáŸí ÜÈÉ A¨Ü®Üá° ×í£ÃÜáXÔ Æ»ÜÂËÃÜáÊÜ ÍæÅà~¿á ±ÜıÜä|ìÊÝ Ü ¸æàÃæ ±ÜÅÍæ° ±ÜâÔ¤Pæ¿á®Üá° ±Üvæ¿áñÜPÜR¨Üáª.
2. A»Ü¦ì¿áá ±ÜÅÍæ° ±ÜâÔ¤Pæ¿á ÍæÅà~ A, B, C A¥ÜÊÝ D A®Üá° ËÐÜ¿á ÓÜíPæàñÜ ÊÜáñÜᤠ®æãàí Ü~ ÓÜíTæ¿á®Üá° OMR EñܤÃÜ ±Ü£ÅPæ¿áÈÉ A¨ÜPÝRX J¨ÜXÓÜÇÝXÃÜáÊÜ ÓܧÙܨÜÈÉ ŸÃæ¨Üá ÓÜíPæàñÜ (G®… Pæãàv…) WæãÚÓܸæàPÜá. ÖÝWÜã ¯WÜ©ñÜ ÓܧÙÜ ÜÈÉ ñÝÊÜâ ÊÜáñÜᤠÓÜíËàûÜPÜÃÜá ÓÜ× ÊÜÞwÃÜáÊÜâ¨Ü®Üá° SbñÜ ±ÜwÔPæãÙÜÛ æàPÜá. J.Gí.BÃ…. ÖÝÙæ¿áÈÉ £ÚÔÃÜáÊÜ ¿ÞÊÜâ¨æà ÊÜÞ×£¿á®Üá° »Ü£ì ÊÜÞvÜáÊÜâ Üá/G®… Pæãàv… ÊÜÞvÜáÊÜâ¨Üá A»Ü¦ìWÜÙÜ gÊݸݪĿÞXÃÜáñܤ¨æ. Jí¨Üá ÊæàÙæ »Ü£ì ÊÜÞvÜ©¨ÜªÈÉ/ñܲ³¨ÜÈÉ AíñÜÖÜ J.Gí.BÃ…. EñܤÃÜ ÖÝÙæ¿á®Üá° £ÃÜÓÜRÄÓÜÇÝWÜáÊÜâ Üá.
3. ±ÜPÜR ÜÈÉ J ÜXÔÃÜáÊÜ aèPÜ ÜÇæÉà ¯ÊÜá¾ ®æãàí Ü~ ÓÜíTæ¿á®Üá°
®ÜÊÜáã©ÓÜ æàPÜá. ±ÜÅÍæ° ±ÜâÔ¤Pæ¿áÈÉ ¸æàÃæ H®Ü®Üã° ŸÃæ¿á¸ÝÃܨÜá.
4. D ±ÜÅÍæ° ±ÜâÔ¤Pæ 100 ±ÜÅÍæ°WÜÙÜ®Üá° JÙÜWæãíwÃÜáñܤ æ. ±ÜÅ£Áãí¨Üá ±ÜÅÍæ°¿áá 4 ±ÜÅ£QÅÁáWÜÙÜ®Üá° (EñܤÃÜWÜÙÜ®Üá°) JÙÜWæãíwÃÜáñܤ æ. ¯àÊÜâ EñܤÃÜ ÖÝÙæ¿áÈÉ WÜáÃÜáñÜá ÊÜÞvܸæàPæ¯ÓÜáÊÜ EñܤÃÜÊÜ®Üá° BÁáR ÊÜÞwPæãÚÛ. Jí Üá ÊæàÙæ AÈÉ Jí¨ÜQRíñÜ ÖæaÜác ÓÜÄ¿Þ Ü EñܤÃÜWÜÚÊæÁáí¨Üá ¯àÊÜâ »ÝËÔ¨ÜÃæ ¯ÊÜáWæ AñÜáÂñܤÊÜáÊæ ÓÜáÊÜ EñܤÃÜPæR WÜáÃÜáñÜá ÊÜÞw. H®æà A¨ÜÃÜã ±ÜÅ£ ±ÜÅÍæ°Wæ ¯àÊÜâ PæàÊÜÆ Jí Üá EñܤÃÜÊÜ®Üá° ÊÜÞñÜÅ BÁáR ÊÜÞvÜ æàPÜá.
5. GÇÝÉ EñܤÃÜWÜÙÜ®Üá° ¯ÊÜáWæ J ÜXÓÜÇÝXÃÜáÊÜ ±ÜÅñæÂàPÜ EñܤÃÜ ÖÝÙæ¿á ÊæáàÇæ PæàÊÜÆ PܱÜâ³ A¥ÜÊÝ ¯àÈ ÍÝÀá¿á ¸ÝÇ…±ÝÀáíp… ±æ °®ÜÈÉ ÊÜÞñÜÅ WÜáÃÜáñÜá ÊÜÞvÜ æàPÜá. J.Gí.BÃ…. EñܤÃÜ ±Ü£ÅPæ ÖÝÙæ¿áÈÉ®Ü ËÊÜÃÜÊÝ¨Ü ÓÜãaÜ®æWÜÙÜ®Üá° WÜÊÜá¯ÓÜáÊÜâ¨Üá.
6. GÇÝÉ ±ÜÅÍæ°WÜÚWæ ÓÜÊÜÞ®Ü AíPÜWÜÙÜá. GÇÝÉ ±ÜÅÍæ°WÜÚWæ EñܤÄÔÄ. ±ÜÅ£ ñܱÜâ³ EñܤÃÜPæR ±ÜÅÍæ°Wæ ¯WÜ©±ÜwÔ Ü AíPÜWÜÙÜ ¼ (0.25) ÃÜÐÜár AíPÜWÜÙÜ®Üá° PÜÙæ¿áÇÝWÜáÊÜâ Üá.
7. bñÜᤠPæÆÓÜPÝRX ÖÝÙæWÜÙÜ®Üá° ±ÜÅÍæ° ±ÜâÔ¤Pæ¿á Pæã®æ¿áÈÉ ÓæàÄÓÜÇÝX¨æ. ±ÜÅÍæ° ±ÜâÔ¤Pæ¿á C®Üá°Ú Ü ¿ÞÊÜ »ÝWܨÜÈÉ¿áã ¯àÊÜâ ¿ÞÊÜ Äࣿá WÜáÃÜáñÜ®Üá° ÊÜÞvÜñÜPÜR ܪÆÉ.
8. ±ÜÄàûæ¿á ÊÜááPݤ¿áÊÜ®Üá° ÓÜãbÓÜáÊÜ Aí£ÊÜá WÜípæ ¸ÝÄÔ Ü ñÜûÜ|Êæà EñܤÃÜ ±Ü£ÅPæ ÖÝÙæ¿áÈÉ C®Ý°ÊÜâ¨æà WÜáÃÜáñÜá ÊÜÞvÜáÊÜâ Ü®Üá° ¯ÈÉÓܸæàPÜá. ÓÜíËàûÜPÜÃÜá Ÿí¨Üá ¯ÊÜá¾ÈÉÃÜáÊÜ EñܤÃÜ ÖÝÙæ¿á®Üá° ñÜÊÜá¾ ÊÜÍÜPæR ±Üvæ ÜáPæãívÜá ÇæPÜRPæR ñæWæ¨ÜáPæãÙÜáÛÊÜÊÜÃæWÜã ¯ÊÜá¾ ¯ÊÜá¾ BÓÜ®Ü ÜÈÉÁáà PÜáÚ£ÃÜñÜPÜR Üáª.
9. ±ÜÅÍæ°WÜÙÜá PܮܰvÜ ÊÜáñÜᤠBíWÜÉ »ÝÐæ¿áÈÉÃÜáñܤÊæ. PܮܰvÜ ±ÜÅÍæ°WÜÙÜÈÉ ÓÜí¨æàÖÜ EípÝ ÜÃæ, Ü¿áËoár BíWÜÉ »ÝÐæ¿á ±ÜÅÍæ°WÜÙÜ®Üá° WÜÊÜá¯ÓÜáÊÜâ¨Üá. ±ÜÅÍæ° ±Ü£ÅPæ¿á ±ÜÅÍæ°WÜÙÜÈÉ ¿ÞÊÜâ¨æà Wæãí¨ÜÆWÜڨܪÃÜã BíWÜÉ»ÝÐæ¿á ±ÜÅÍæ°WÜÙæà Aí£ÊÜáÊÝXÃÜáñܤ¨æ.
Note : English version of the instructions is printed on the back cover of this booklet.
A ËÐÜ¿á ÓÜíPæàñÜ : 235
*235/A*
®æãàí¨Ü~ ÓÜíTæÂ
¿ÞÊÜâ æà Äࣿá Êæã æçÇ… ¶æäà®…, PÝÂÇ…PÜáÂÇæàoÃ… ÊÜáñÜᤠCñÜÃæ Äࣿá GÇæPÝó¯P…/PÜÊÜáã¯PæàÐÜ®… ÓÝ«Ü®ÜWÜÙÜá CñÝ©WÜÙÜ®Üá° ±ÜÄàûÝ Pæàí¨ÜÅ Ü BÊÜÃÜ|¨æãÙÜWæ ñÜÃÜáÊÜâ Ü®Üá° ¯Ðæà˜Ô¨æ.
235 (2 – A )
1. JvÀÛgÀzÀ ¥ÀæzÉñÀUÀ½UÉ ºÉÆÃUÀĪÁUÀ ¥Àæw ZÀ®£ÉAiÀÄ PÁ¬Ä¯ÉAiÀÄ OµÀ¢üUÀ¼À£ÀÄß F ¸ÀªÀÄAiÀÄzÀ°è ¤ÃqÀ¨ÉÃPÀÄ
1) ¥ÀæAiÀiÁtPÉÌ ºÀ£ÉßgÀqÀÄ UÀAmÉ ªÉÆzÀ®Ä
2) ¥ÀæAiÀiÁtPÉÌ MAzÀÄ UÀAmÉ ªÉÆzÀ®Ä
3) ¥ÀæAiÀiÁt DgÀA©ü¹zÀ PÀÆqÀ¯É
4) ZÀ®£É PÁ¬Ä¯ÉAiÀÄ ªÉÆzÀ® sÁªÀ §AzÀ PÀÆqÀ¯Éà PÀAqÀ PÀÆqÀ¯ÉÃ
2. AiÀiÁªÀ ¥ÉÆæPÉÊ£ÉnPï ªÀÄzÀÄÝ JPïìmÁæ¦gÀ«ÄqÀ¯ï CqÀØ¥ÀjuÁªÀÄ GAlĪÀiÁqÀÄvÀÛzÉ?
1) ªÉÄmÉÆPÉÆè¥ÀæªÉÄÊqï
2) ¹¸Á¥ÉæöÊqï
3) qÉƪÀiï¥ÉjqÉÆãï
4) F J®èªÀÇ
3. PÁnðPÉÆùÖÃgÁAiÀiïØ aQvÉì F PɼÀV£À gÉÆÃUÀUÀ¼À£ÀÄß G®âtUÉƽ¸ÀĪÀÅzÀÄ, EzÀ£ÀÄß ºÉÆgÀvÀÄ¥Àr¹
1) PÀAfäl¯ï Cræ£À¯ï ºÉÊ¥Àgï ¥ÉèùAiÀiÁ
2) qÀAiÀiÁ©n¸ï ªÉÄ°l¸ï
3) ºÉÊ¥Àgï mÉ£Àë£ï
4) ¥É¦ÖPï C®ìgï
4. eÉÆæPÉÆèãïUÉ ¸ÀA§A¢ü¹zÀAvÉ F ¥ÉÊQ AiÀiÁªÀ ºÉýPÉ ¸ÀjAiÀÄ®è?
1) CzÀÄ £Á£ÉâAeÉÆÃrAiÀiÁeÉ¥ÉÊ£ï ¸ÀªÉÆäúÀPÀ ªÀÄvÀÄÛ ¨ÉAeÉÆÃqÀAiÉÆeÉ¥ÉÊ£ïUÀ½UÉ ºÉÆîĪÀ ¸ÀÄgÀPÀëvÉ ªÀÄvÀÄÛ PÁAiÀÄð¹¢ÞAiÀÄzÀÄ
2) CzÀÄ ¸ÉêÀ£É ¤°è¹zÀ PÀÆqÀ¯Éà ªÀÄgÀÄPÀ½¹zÀ ¤zÁæ»Ã£ÀvÉ GAlĪÀiÁqÀzÀÄ
3) fJ©JAiÀÄ£ÀÄß G¢ÝÃ¥À£ÀUÉƽ¹ PÁAiÀÄð¤ªÀð»¸ÀzÀÄ
4) ¤AiÀÄ«ÄvÀªÁzÀ ¨ÉAeÉÆÃqÀAiÀÄeÉ¦Ã£ï §¼ÀPÉ ªÀiÁqÀĪÀ ¤zÁæ»Ã£ÀvÉAiÀĪÀgÀ ZÀl vÀ¦à À®Ä §¼ÀPÉ DUÀĪÀÅzÀÄ
5. F ¥ÉÊQ AiÀiÁªÀÅzÀÄ ¹.J£ï.J¸ï T£ÀßvÉPÁgÀPÀ C®è DzÀgÉ gÁwæAiÀÄ°è UÁqsÀ¤zÉæ §gÀĪÀAvÉ ªÀiÁqÀĪÀÅzÀÄ
1) ¦jqÁQì£ï
2) qÉʦüºÉÊqÀæ«Ä£Ë
3) ªÉįÁmÉƤ£ï
4) JxÀ£Á¯ï
6. ¸ÉÆÃrAiÀĪÀiï ªÁ¯ÉÆàgÉÃmï C£ÀÄß QjAiÀÄgÀ°è §¼ÀPÉ ªÀiÁqÀĪÁUÀ JZÀÑjPÉ ªÀ»¸À¨ÉÃPÀÄ KPÉAzÀgÉ CzÀgÀ°è F §UÉAiÀÄ CqÀØ¥ÀjuÁªÀÄzÀ C¥ÁAiÀÄ«zÉ
1) ºÉ¥ÀmÉÊn¸ï
2) PÀÆzÀ®Ä GzÀÄgÀÄ«PÉ
3) C£ÉÆÃgÉQìAiÀiÁ
4) mÉæªÀÄgï
235 (3 – A )
1. In case of high altitude journey,
anti-motion sickness drugs are best
administered at :
1) Twelve hours before
commencing journey
2) One hour before commencing
journey
3) Immediately after commencing
journey
4) At the first feeling of motion
sickness
2. Which prokinetic drug produce extra
pyramidal side effects :
1) Metoclopramide
2) Cisapride
3) Domperidone
4) All of the above
3. Corticosteroid therapy can aggravate
the following disorders Except:
1) Congenital adrenal hyperplasia
2) Diabetes mellitus
3) Hypertension
4) Peptic ulcer
4. Which of the following statements is
not true of zopiclone:
1) It is a nonbenzodiazepine
hypnotic with efficacy and safety
similar to benzodiazepines
2) It does not produce rebound
sleep disturbances on
discontinuation
3) It does not act by potentiating
GABA
4) It is used to wean off insomniacs
from regular benzodiazepine use
5. Which of the following is not a CNS
depressant but increases the tendency
to fall asleep at night:
1) Pyridoxine
2) Diphenhydramine
3) Melatonin
4) Ethanol
6. Sodium valproate should be used with
caution in young children because
they are particularly at risk of
developing the following adverse
effect:
1) Hepatitis
2) Loss of hair
3) Anorexia
4) Tremor
235 (4 – A )
7. ¹¸ï¥Áèn£ï G¢ÝævÀ ªÁAwAiÀÄ ¤AiÀÄAvÀætPÉÌ CvÀåAvÀ ¥ÀjuÁªÀÄPÁj ªÀªÀÄ£À±ÁªÀÄPÀ
1) ¥ÉÆæPÉÆèÃgï¥ÉgÀf£ï
2) MAqÀ£À¸ÉmÁæ£ï
3) ªÉÄmÉÆPÉÆè¥ÀæªÉÄÊqï
4) ¥ÉÆæ«ÄxÀgÉhÄÊãï
8. ¥ÉÆæÃ¥Àæ£ÉƯÁ¯ï CqÀæ£À°£ï£À F PÁAiÀÄðUÀ¼À£ÀÄß CqÀØ¥Àr¸ÀzÀÄ
1) ¨ÁæAPÉÆr®mÉõÀ£ï (±Áé À£Á¼À)
2) °¥ÉÆð¹¸ï
3) ¸ÁßAiÀÄÄ PÀA¥À£À
4) «ÄræAiÀÄƹ¸ï
9. ¹¯ÉØ£À¦ü¯ï C£ÀÄß F PɼÀV£À OµÀ¢ü ¸Éë¸ÀĪÀ gÉÆÃVUÀ½UÉ ¥Àæw §A¢ü¸À¯ÁVzÉ 1) - CqÉæ£ÀfðPï ¨ÁèPÀgïì 2) - CqÉæ£ÀfðPï ¨ÁèPÀgïì 3) DUÁåð¤Pï £ÉÊmÉæöÊmïì 4) DAfAiÉÆÃmɤì£ï ¥ÀjªÀwð¸ÀĪÀ Qté
¤µÉÃzsÀPÀUÀ¼ÀÄ
10. ¯ÉÆêÀÄ£Á¼ÀUÀ¼À ªÀÄÆ®PÀ ªÀÄzÀÄÝUÀ¼À£ÀÄß ªÁ妸ÀĪÀÅzÀÄ «ÄzÀĽ£À°è ºÉÆgÀvÀÄ¥Àr¹ ¤AiÀÄAwæ¸ÀĪÀ CA±ÀªÉAzÀgÉ
1) ¯ÉÆêÀÄ£Á¼ÀUÀ¼À ªÀÄÆ®PÀ gÀPÀÛ ºÀjªÀÅ
2) ªÀĢݣÀ °¦qï «°Ã£ÀvÉ
3) OµÀ¢üAiÀÄ pKa ªÀiË®å
4) ªÀiÁzsÀåªÀÄzÀ pH
11. ZÀªÀÄð ¸ÀĹÜwAiÀÄ°èzÁÝUÀ »ÃjPÉ ¤AiÀÄAwæ¸ÀĪÀ ¥ÀæªÀÄÄR CA±À 1) ªÀĢݣÀ CtÄ vÀÆPÀ 2) C£ÀéAiÀÄzÀ ¸ÀܼÀ 3) ªÀĢݣÀ °¦qï «°Ã£ÀvÉ 4) gÀZÀ£É®AiÀÄ°è G¥ÀAiÉÆÃV¸ÀĪÀ DzsÁgÀ
ªÀ¸ÀÄÛ
12. ©üÃwAiÀÄ ªÀÄvÀÄÛ ¢ézsÀÄæªÀ PÁ¬Ä¯ÉUÀ¼À°è F PɼÀV£À ªÀÄzÀÝ£ÀÄß °ÃyAiÀÄ£ïUÉ ¥ÀAiÀiÁðAiÀĪÁV §¼ÀPÉ ªÀiÁqÀ§ºÀÄzÀÄ
1) PÁ§ðªÀÄeÉ¥ÉÊ£ï
2) PÁåj¸ÉÆÃ¥ÉÆæÃqÀ¯ï
3) PÉÆèëĥÀæªÉÄÊ£ï
4) qÉÊFxÉʯï PÁ§ðªÀÄeÉÊ£ï
13. AiÀÄPÀÈwÛ£À°è ªÉÆzÀ®Ä ¸ÁV ZÀAiÀiÁ¥ÀZÀAiÀÄ QæAiÉÄUÀ½UÉ M¼ÀUÁUÀĪÀ ªÀÄzÀ£ÀÄß DAiÉÄ̪ÀiÁr
1) ¦ü£ÉÆèÁ©ðmÉÆ£ï 2) ¥ÉÆæ¥Àæ£ÉƯÁ¯ï 3) ¦ü£ÉÊ¯ï §ÄåleÉÆãï 4) yAiÉÆÃ¥sÉÊü°£ï
14. ¥É¤¹°£À-f AiÀÄ ¥Áè¸Áä CgÉ DAiÀÄĵÀå £ÀªÀeÁvÀ ²±ÀÄ«£À°è C¢üPÀ DVgÀ®Ä PÁgÀt
1) ¥Áè¸Áä ¥ÉÆæÃnãÀÄ ªÀÄlÖªÀÅ PÀrªÉÄ
2) ªÀÄzÀÄÝ ZÀAiÀiÁ¥ÀZÀAiÀÄ QtéUÀ¼ÀÄ C¥Àæ§ÄzÀÞ
3) UÉÆèªÉÄgÀÄ®gï ±ÉÆÃzsÀ£É zÀgÀ PÀrªÉÄ
4) lÆå§Ä®gï ªÀUÁðªÀuÉ QæAiÀiÁ«£Áå¸ÀUÀ¼ÀÄ E£ÀÆß C©üªÀÈ¢ÞUÉÆAr®è¢gÀĪÀÅzÀÄ
235 (5 – A )
7. The most effective antiemetic for
controlling cisplatin induced vomiting
is:
1) Prochlorperazine
2) Ondansetron
3) Metoclopramide
4) Promethazine
8. Propranolol does not block the
following action of adrenaline:
1) Bronchodilatation
2) Lipolysis
3) Muscle tremor
4) Mydriasis
9. Sildenafil is contraindicated in
patients taking the following class of
drugs:
1) - adrenergic blockers
2) - adrenergic blockers
3) Organic nitrates
4) Angiotensin converting enzyme
inhibitors
10. The most important factor which
governs diffusion of drugs across
capillaries other than those in the
brain is:
1) Blood flow through the capillary
2) Lipid solubility of the drug
3) pKa value of the drug
4) pH of the medium
11. The most important factor governing
absorption of a drug from intact skin
is:
1) Molecular weight of the drug
2) Site of application
3) Lipid solubility of the drug
4) Nature of the base used in the
formulation
12. The following drug can be used as an
alternative to lithium in mania and
bipolar illness:
1) Carbamazepine
2) Carisoprodol
3) Clomipramine
4) Diethyl carbamazine
13. Select the drug that undergoes
extensive first-pass metabolism in the
liver.
1) Phenobarbitone
2) Propranolol
3) Phenylbutazone
4) Theophylline
14. The plasma half life of penicillin-G is
longer in the new born because their:
1) Plasma protein level is low
2) Drug metabolizing enzymes are
immature
3) Glomerular filtration rate is low
4) Tubular transport mechanisms
are not well Developed
235 (6 – A )
15. MAzÀÄ OµÀ¢üÃAiÀÄ (qÀæUï) ¯ÉÆÃrAUï qÉÆøï£ÀÄß CzÀgÀ ________ ¤AiÀÄAwæ¸ÀÄvÀÛzÉ.
1) ªÀÄÆvÀæzÀ ªÀÄÆ®PÀ «¯ÉêÁj
2) ¥Áè¸Áä CzsÁðAiÀÄĵÀå
3) «vÀgÀuÉ UÁvÀæ
4) «¯ÉêÁj zÀgÀ ¹ÜgÁAPÀ
16. F PɼÀV£À J®èªÀÇ CAvÀgÀ fêÀPÉÆòÃAiÀÄ ¸ÀAzÉñÀªÁºÀPÀUÀ¼ÁV ¸ÀéPÁgÀPÀ ªÀÄzsÀå¹ÜPÉ ¸ÀAeÉÕ ªÀUÁðªÀuÉAiÀÄ°è C¢üãÀªÁV ªÀwð¸ÀÄvÀÛªÉ EzÀ£ÀÄß ºÉÆgÀvÀÄ¥Àr¹
1) ¸ÉÊQèPï JJªÀiï¦
2) E£Á¹l¯ï mÉæöÊ¥sÁ¸ÉÒÃmï
3) qÉÊC¸Éʯï Vè¸ÀgÁ¯ïUÀ¼ÀÄ
4) f ¥ÉÆæÃn£ïUÀ¼ÀÄ
17. jãÀ¯ï C¸ÀªÀÄ¥ÀðPÀvÉ EgÀĪÀ gÉÆÃVUÀ¼À°è F PɼÀV£À ªÀĢݣÀ «¯ÉÃAiÀÄÄ QæAiÉÆÃn¤£ï «¯ÉÃAiÀÄ vÀVÎUÉ ¸ÀªÀiÁAvÀgÀªÁV vÀVθÀÄvÀÛzÉ.
1) ¥ÉÆæ¥Àæ£ÉƯÁ¯ï
2) qÉÊUÁQì£ï
3) °UÉÆßPÉÊ£ï
4) ªÉgÀ¥À«Ä¯ï
18. C£Á¦ü¯ÁQÖÖPï CWÁvÀ DzÁUÀ CqÀæ£À°£ï ¥ÀÆgÉÊPÉAiÀÄ Cw ¸ÀªÀÄ¥ÀðPÀ ºÁ¢ 1) EAmÁæPÁrðAiÀiÁPï 2) EAmÁæ«Ã£À¸ï 3) EAmÁæªÀĸÀÄÌöå®gï 4) ¸À¨ïPÀÄmÉäAiÀĸï
19. (©ÃmÁ) CqÉæ£ÀfðPÀ ¥Àæw §A¢üPÀªÀÅ, ºÉZÀÄѪÀj 1 ¥Àæw§AzsÀ£É, ªÁå¸ÉÆÌqÉʯÉÃlgï ªÀÄvÀÄÛ ¥Àæw DQìqÀQ UÀÄtzsÀªÀÄð ºÉÆA¢gÀĪÀÅzÀ£ÀÄß DAiÉÄ̪ÀiÁr
1) PÁªÉðqÉʯÁ¯ï 2) ¸É°¥ÉÆæ¯Á¯ï 3) C¸É§ÄåmÉÆïÁ¯ï 4) ªÉÄmÉÆ¥ÉÆæ¯Á¯ï
20. ¥ÉæÃgÀPÀ ªÀÄzÀÄÝ JAzÀgÉ 1) ªÀÄzÀÄÝ ªÀUÀðzÀ ¥ÀƪÀð ªÀiÁzÀj ¸ÀzÀ¸Àå 2) ªÀÄzÀÄÝ ªÀUÀðzÀ ºÀ¼ÉAiÀÄ ¸ÀzÀ¸Àå 3) ¤¶ÌçAiÀĪÁVzÀÝ ªÀÄzÀÄÝ zÉúÀzÉƼÀUÉ
¸ÀQæAiÀÄ ZÀAiÀiÁ¥ÀZÀAiÀÄPÁjAiÀiÁUÀĪÀÅzÀÄ 4) zÉúÀzÀ CAUÁA±ÀUÀ¼À°è ¸ÀAUÀæºÀªÁV
PÀæªÉÄÃt gÀPÀÛ¥ÀjZÀ®£ÉUÉ PÀæªÉÄÃt ©qÀÄUÀqÉ ªÀiÁqÀĪÀAvÀºÀ ªÀÄzÀÄÝ
21. gÀÆrüUÀvÀªÁV ¸Éë¸ÀÄwÛzÀÝ F ªÀĢݣÀ ¸ÉêÀ£ÉAiÀÄ£ÀÄß ¢rüÃgï ¤°è¹zÁUÀ ¥ÀæwPÀÆ® ¥ÀjuÁªÀÄ ©ÃgÀĪÀAvÀºÀzÀÄ 1) PÉÆPÉãï 2) PÀ£Áß©¸ï 3) PÉÆèäqÉÊ£ï 4) F ªÉÄð£À J®èªÀÇ
22. ¹ÖgÁAiÉÄØÃvÀgÉ GjAiÀÄÆvÀgÀ»vÀ ªÀÄzÀÄÝUÀ¼ÀÄ ªÉÄÊUÉæãï£À°è ºÉZÀÄÑ ¥ÀjuÁªÀÄPÁj
1) OgÁgÀ»vÀ 2) OgÁ¸À»vÀ 3) JUÉÆðlªÉÄÊ£ïVAvÀ 4) ¥ÉÆæ¥Àæ£ÉƯÉÆïï eÉÆvÉUÉ ¨ÉgÉvÁUÀ
235 (7 – A )
15. The loading dose of a drug is
governed by its:
1) Renal clearance
2) Plasma half life
3) Volume of distribution
4) Elimination rate constant
16. All of the following subserve as
intracellular second messengers in
receptor mediated signal transduction
Except:
1) Cyclic AMP
2) Inositol trisphosphate
3) Diacyl glycerols
4) G proteins
17. In patients with renal insufficiency
the clearance of the following drug is
reduced parallel to the reduction in
creatinine clearance:
1) Propranolol
2) Digoxin
3) Lignocaine
4) Verapamil
18. The most appropriate route of
administration for adrenaline in a case
of anaphylactic shock is:
1) Intracardiac
2) Intravenous
3) Intramuscular
4) Subcutaneous
19. Select the β-adrenergic blocker that
has additional αl blocking, vasodilator
and antioxidant properties:
1) Carvedilol
2) Celiprolol
3) Acebutolol
4) Metoprolol
20. A prodrug is
1) The prototype member of a class
of drugs
2) The oldest member of a class of
drugs
3) An inactive drug that is
transformed in the body to an
active metabolite
4) A drug that is stored in body
tissues and is then gradually
released in the circulation
21. Adverse consequences may follow
sudden discontinuation of the
following drug after chronic intake:
1) Cocaine
2) Cannabis
3) Clonidine
4) All of the above
22. The nonsteroidal antiinflammatory
drugs are more effective in migraine:
1) Without aura
2) With aura
3) Than ergotamine
4) When combined with
propranolol
235 (8 – A )
23. ¨ÉÃ¥ÀðrPÉ CjªÀ½PÉ GAlĪÀiÁqÀĪÀÅzÀÄ EzÀÄ:
1) PÉlªÉÄÊ£ï
2) ¥sÉAmÁ¤¯ï
3) ¥ÉÆæ¥ÉÆ¥sÁ¯ï
4) ‘J’ ªÀÄvÀÄÛ ‘©’ JgÀqÀÆ ¸Àj
24. ¥Àæw ¸ÉÊPÉÆÃnPï ªÀÄzÀÄÝ, DPÀÆå®gï mÁQì¹nAiÀÄ£ÀÄß ¢ÃWÀðPÁ°PÀ §¼ÀPÉ £ÀAvÀgÀ GAlĪÀiÁqÀĪÀAvÀºÀzÀÄ
1) yAiÉÆÃjqÀf£ï
2) ºÁå¯ÉÆÃ¥ÉjqÁ¯ï
3) ¥sÀÄè¥ÉAwPÁì¯ï
4) ¦ªÉÆeÉÊqï
25. ªÉÄUÀ¯ÉƨÁè¹ÖPï C¤Ã«ÄAiÀÄ DUÀ¨ÉÃPÁzÀgÉ
1) «l«Ä£ï ‘©12’ PÉÆgÀvÉ PÁgÀt,¥sÉÆðPï DªÀÄè PÉÆgÀvÉ C®è
2) ¥sÉÆðPï DªÀÄè PÉÆgÀvÉ PÁgÀt, «l«Ä£ï ‘©12’ PÉÆgÀvÉ C®è
3) «l«Ä£ï ‘©12’ CxÀªÁ ¥sÉÆðPï DªÀÄè JgÀqÀgÀ PÉÆgÀvÉAiÀiÁUÀ°Ã C®è
4) «l«Ä£ï ‘©12’ + ¥sÉÆðPï DªÀÄèzÀ ¸ÀAAiÉÆÃd£ÉAiÀÄ PÉÆgÀvÉ ªÀiÁvÀæ
26. F PɼÀV£À ªÀÄzÀÄÝ ¥ÀæwUÀgÀuÉPÁgÀPÀUÀ¼À ¥ÀjuÁªÀÄ vÀVθÀÄvÀÛzÉ
1) «±Á® ªÁå¥ÀPÀ ªÁå¦ÛAiÀÄ ¥Àæw fêÀPÀ
2) ¹ªÉÄmÉÊqÉÊ£ï
3) D¹àj£ï
4) ªÀiËTPÀ UÀ sÀð¤gÉÆÃzsÀPÀ
27. ¸ÁªÀiÁ£Àå CjªÀ½PÉUÀ¼ÀÄ £ÉÆêÀÅPÁgÀPÀ ±À¸ÀÛç aQvÉìAiÀÄ°è ¥ÁæxÀ«ÄPÀªÁV ¤±ÀÑ®vÉAiÀÄ£ÀÄß GAlĪÀiÁqÀĪÀÅzÀÄ 1) ªÉÆÃlgï PÁmÉðPïì 2) ¨Á¸À¯ï UÁåAVèAiÀiÁ 3) xÁ®ªÀĸï 4) ¨É£ÀÄߺÀÄj
28. ¥ÉÆæÃeÉ¹Ö£ï ªÀÄvÀÄÛ J¸ÉÆÖçÃd£ïUÀ¼À£ÀÄß ªÀiËTPÀ UÀ sÀð¤gÉÆÃzsÀPÀ UÀĽUÉAiÀÄ°è ¸ÀAAiÉÆÃf¸À®Ä PÁgÀt
1) J¸ÉÆÖçÃd£ï ¥ÉÆæeɹ֣ï£À CqÀØ ¥ÀjuÁªÀĪÀ£ÀÄß ¥Àæw§A¢ü ÀÄvÀÛzÉ
2) ¥ÉÆæeɹ֣ï J¸ÉÆÖçÃeÉ£ï£À CqÀØ ¥ÀjuÁªÀĪÀ£ÀÄß ¥Àæw§A¢ü ÀÄvÀÛzÉ
3) ºÀwÛQÌzÀ CAqÉÆÃvÀàwÛAiÀÄ£ÀÄß JgÀqÀÆ ¹£ÀgïeÉÊ¸ï ªÀiÁqÀÄvÀÛzÉ
4) ºÉƸÉÖöÊ¯ï ¸À«ðPÀ¯ï ªÀÄÆåPÀ¸ï GvÀàwÛAiÀÄ£ÀÄß JgÀqÀÆ ¹£ÀgïeÉÊ¸ï ªÀiÁqÀÄvÀÛªÉ.
29. ¦¯ÉÆPÁ¦ð£ï PÀtÄÚ ºÀ¤UÀ½VAvÀ nªÉƯÁ¯ï PÀtÄÚ ºÀ¤UÀ¼ÀÄ UÀÆèPÉÆêÀÄ gÉÆÃVUÀ½UÉ GvÀÛªÀĪÁVgÀ®Ä PÁgÀt
1) nªÉƯÉÆÃ¯ï ¦¯ÉÆPÁ¦ð£ïVAvÀ ºÉZÀÄÑ ¥ÀjuÁªÀÄPÁj
2) nªÉƯÉƯï AiÀÄÆ«AiÉÆøÉÌgÀ¯ï ºÉÆgÀ ºÀjªÀ£ÀÄß ºÉaÑ ÀĪÀ ªÀÄÆ®PÀ PÁAiÀÄð¤ªÀð»¸ÀÄvÀÛzÉ
3) nªÉƯÉƯï PÀtÂÚUÉ PÀrªÉÄ CqÀØ ¥ÀjuÁªÀĪÀÅAlÄ ªÀiÁqÀÄvÀÛzÉ
4) nªÉƯÉƯïUÉ ªÀåwjPÀÛ aºÉßUÀ¼ÀÄ E®è
235 (9 – A )
23. ‘Dissociative anaesthesia’ is produced
by:
1) Ketamine
2) Fentanyl
3) Propofol
4) Both ‘A’ and ‘B’ are correct
24. The antipsychotic drug most likely to
cause ocular toxicity on long-term use
is:
1) Thioridazine
2) Haloperidol
3) Flupenthixol
4) Pimozide
25. Megaloblastic anaemia occurs in:
1) Vitamin B12 but not folic acid
deficiency
2) Folic acid but not Vitamin B12
deficiency
3) Either Vitamin B12 or folic acid
deficiency
4) Only combined Vitamin B12 +
folic acid deficiency
26. The following drug reduces the effect
of oral anticoagulants:
1) Broad spectrum antibiotic
2) Cimetidine
3) Aspirin
4) Oral contraceptive
27. General anaesthetics produce
immobility in response to painful
surgical stimuli by acting primarily at
the:
1) Motor cortex
2) Basal ganglia
3) Thalamus
4) Spinal cord
28. A progestin and an estrogen are
combined in oral contraceptive pill
because:
1) The estrogen blocks the side
effects of the progestin
2) The progestin blocks the side
effects of the estrogen
3) Both synergise to suppress
ovulation
4) Both synergise to produce hostile
cervical Mucus
29. Timolol eye drops are preferred over
pilocarpine eye drops by glaucoma
patients because:
1) Timolol is more effective than
pilocarpine
2) Timolol acts by enhancing uveo-
scleral outflow
3) Timolol produces less ocular
side effects
4) There are no contraindications to
timolol
235 (10 – A )
30. ªÉÄxÀ£Á¯ï «µÀzÀ°è, ExÉ£Á¯ï£ÀÄß §¼ÀPÉ ªÀiÁqÀ®Ä PÁgÀtªÉAzÀgÉ
1) CzÀÄ ªÉÄxÀ£Á¯ï ZÀAiÀiÁ¥ÀZÀAiÀÄ QæAiÉÄAiÀÄ£ÀÄß CzÀjAzÁUÀĪÀ £ÀAdÄ GvÀà£ÀߪÀ£ÀÄß vÀqÉAiÀÄÄvÀÛzÉ
2) ªÉÄxÀ£Á¯ï ZÀAiÀiÁ¥ÀZÀAiÀÄ QæAiÉÄAiÀÄ£ÀÄß ¥ÀæZÉÆâ¹ gÀPÀÛzÀ°è CzÀgÀ ªÀÄlÖ vÀVθÀÄvÀÛzÉ
3) «ÄxÉ£Á°£À QæAiÉÄAiÀÄ£ÀÄß ¥ÀæwgÉÆâü¸ÀÄvÀÛzÉ
4) «ÄxÉ£Á¯ï £Á±À¥Àr¹zÀ ¥sÉÆïÉÃmï ¸ÀAUÀæºÀªÀ£ÀÄß ªÀÄgÀÄ ¥ÀÆgÉʸÀÄvÀÛzÉ.
31. F PɼÀV£À ¥Àæw PÁå£Àìgï OµÀ¢ü vÉUÉzÀÄPÉÆAqÀªÀgÀÄ D¯ÉÆ̺Á¯ï ¸Éë¹zÀgÉ qÉʸÀ¯ï¦ügÁªÀiï£ÀAvÀºÀ ¥ÀæwQæAiÉÄUÉ M¼ÀUÁUÀÄvÁÛgÉ.
1) qÉÊPÁ§ðeÉÊ£ï
2) ¥ÉÆæPÁ§ðeÉÊ£ï
3) ªÉĮᮣï
4) ºÉÊqÁæQìAiÀÄÆjAiÀiÁ
32. ªÉÄ£ÉÆqÉÊAiÉÆ£ï («l«Ä£ï K3) PɤðPÀÖgÀ¸ï C£ÀÄß »ÃUÉ GAlÄ ªÀiÁqÀÄvÀÛzÉ
1) »ÃªÀiÁ¯É¹¸ï£ÀÄß ¥ÉæÃj¸ÀÄvÀÛzÉ
2) ©°gÀÄ©£ï£À UÀÄèPÉÆÃgÉƤqÉõÀ£ï£ÀÄß ¥Àæw §A¢ü¸ÀÄvÀÛzÉ.
3) ¥Áè¸Àä ¥ÉÆæÃnÃ£ï §zÀÞ ©®ÄgÀÄ©£À£ÀÄß ¥À®èl¸ÀÄvÀÛzÉ.
4) (1) ªÀÄvÀÄÛ (2) JgÀqÀÆ ¸Àj
33. ªÀiËTPÀ PÀ©âuÁA±ÀzÀ ¸ÉêÀ£ÉAiÀÄ »ÃjPÉAiÀÄ eÉÆvÉAiÀÄ°è EzÀ£ÀÄß ¤Ãr ªÀÄvÀÛµÀÄÖ ¸ÀÄUÀªÀÄUÉƽ¸À§ºÀÄzÀÄ.
1) DªÀÄèºÁjUÀ¼ÀÄ
2) mÉmÁæ¸ÉÊQè£ïUÀ¼ÀÄ
3) ¥sÁ¸ÉÖÃmïUÀ¼ÀÄ
4) C¸ÁÌ©ðPï DªÀÄè
34. F OµÀ¢ü ¸ÉêÀ£É ªÀiÁqÀĪÀªÀgÀÄ ªÀÄzÀå¸ÉêÀ£É ªÀiÁqÀzÀAvÉ JZÀÑgÀªÀ»¸À¨ÉÃPÀÄ.
1) ªÉĨÉAqÀeÉÆïï
2) ªÉÄmÉÆæäqÀeÉÆïï
3) ªÉÄyªÀÄeÉÆïï
4) ªÉÄl«ÄeÉÆïï
35. EArAiÀÄ£ï ¥sÁªÀÄðPÉÆæAiÀiÁzÀ (IP) K¼À£Éà DªÀÈwÛ ¥ÀæPÀn¹zÀ ªÀµÀð
1) 2010 2) 2014 3) 2016 4) 2017
36. 90% ªÀÄvÀÄÛ 50% D¯ÉÆÌúÁ¯ïUÀ¼À£ÀÄß AiÀiÁªÀ C£ÀÄ¥ÁvÀzÀ°è ¨Égɹ 100 mL, 70% D¯ÉÆÌúÁ¯ï vÀAiÀiÁj¸À§ºÀÄzÀÄ.
1) 45 mL of 90% + 55 mL of 50%
2) 50 mL of 90% + 50 mL of 50%
3) 60 mL of 90% + 40 mL of 50%
4) 70 mL of 90% + 30 mL of 50%
235 (11 – A )
30. Ethanol is used in methanol poisoning
because it;
1) Inhibits the metabolism of
methanol and generation of toxic
metabolite
2) Stimulates the metabolism of
methanol and reduces its blood
level
3) Antagonises the actions of
methanol
4) Replenishes the folate stores
depleted by Methanol
31. Patients treated with the following
anticancer drug are likely to develop a
disulfiram like reaction on taking
alcohol:
1) Dacarbazine
2) Procarbazine
3) Melphalan
4) Hydroxyurea
32. Menadione (Vitamin K3) can produce
kernicterus in neonates by:
1) Inducing haemolysis
2) Inhibiting glucuronidation of
bilirubin
3) Displacing plasma protein bound
bilirubin
4) Both (1) and (2) are correct
33. Absorption of oral iron preparations
can be facilitated by
co-administering:
1) Antacids
2) Tetracyclines
3) Phosphates
4) Ascorbic acid
34. Patients treated with the following
drug should be cautioned not to
consume alcoholic beverages:
1) Mebendazole
2) Metronidazole
3) Methimazole
4) Metamizol
35. The seventh edition of Indian
Pharmacopeia (IP) was published in
the year
1) 2010
2) 2014
3) 2016
4) 2017
36. In what proportions should alcohol of
90% and 50% strengths be mixed to
make 70% of 100 mL alcohol
1) 45 mL of 90% + 55 mL of 50%
2) 50 mL of 90% + 50 mL of 50%
3) 60 mL of 90% + 40 mL of 50%
4) 70 mL of 90% + 30 mL of 50%
235 (12 – A )
37. zsÀ£À DAiÀiÁ£ÀÄ ¸À¥sÁåðPÉÖAmï J®èªÀ£ÀÄß M¼ÀUÉƼÀÄîvÀÛzÉ EzÀ£ÀÄß ºÉÆgÀvÀÄ¥Àr¹
1) ¨ÉAeÁ¯ïPÉÆäAiÀĪÀiï PÉÆèÃgÉÊqï
2) PÁå°ìAiÀĪÀiï N°AiÉÄÃmï
3) ¸ÉÆÃrAiÀĪÀiï ¯Áj¯ï ¸À¯ÉáÃmï
4) ¸ÉÆÃrAiÀĪÀiï ¹ÖAiÀÄgÉÃmï
38. JuÉÚ PÀgÀUÀ§®è ¨ÁºÀåvÀ®¸ÁAzÀævÁºÁæ¸ÀPÀUÀ¼ÀÄ 1) «°Ã£ÀPÀUÉƽ¸ÀĪÀ zÀPÀë ªÀÄzsÀåªÀwð
2) ºÉÊqÉÆææü°PïUÀ¼ÀÄ
3) d®-vÉÊ®-JªÀįï±À£ï£ÀÄß GvÁࢸÀĪÀ JªÀį﹥sÉÊgï DV §¼ÀPÉAiÀiÁUÀÄvÀÛzÉ.
4) C¢üPÀ HLB ªÀiË®åUÀ¼À£ÀÄß¼ÀîªÀÅ
39. PÉÆñÀ ©üwÛAiÀÄ gÁ¸ÁAiÀĤPÀ gÀZÀ£É, UÁæªÀiï ¥Á¹nªï fëUÀ¼À°è F J®èªÀ£ÀÄß M¼ÀUÉÆAqÀÄ EgÀĪÀÅzÀÄ. DzÀgÉ EzÀ£ÀÄß ºÉÆgÀvÀÄ¥Àr¹
1) °¥ÉÆ¥Á°¸ÁåPÀgÉÊqïUÀ¼ÀÄ
2) °¥ÉÆ¥ÉÆæÃnãïUÀ¼ÀÄ
3) ¥É¦ÖqÉÆUÉèöÊPÀ£ïUÀ¼ÀÄ
4) mÉÊPÉÆìÄPï DªÀÄèUÀ¼ÀÄ
40. UÁæªÀiï ¥Á¹nªï PÁPÉÊUÉ GzÁºÀgÀuÉ
1) PÉÆèùÖçrAiÀĪÀiï
2) £ÉʸÉjAiÀiÁ ªÉĤAfmÉÊqïì
3) ¸ÀÆåqÉÆêÉÆ£Á¸ï
4) ¸Áé¥ÉʯÉÆÃPÁPÀ¸ï OjAiÀĸï
41. D¯ÉÆÌúÁ¯ï ºÀÄzÀÄUÀÄ«PÉ ¥ÀæQæAiÉÄAiÀÄ°è
1) ¥ÉÊgÀĪÉÃmï C¹mÉÆãï DV ¥ÀjªÀvÀð£É DUÀĪÀÅzÀÄ
2) ¥ÉÊgÀĪÉÃmï ExÉ£Á¯ï ªÀÄvÀÄÛ PÁ§ð£ï qÉÊ DPÉìöÊqï DV ¥ÀjªÀvÀð£É DUÀĪÀÅzÀÄ
3) ¥ÉÊgÀĪÉÃmï ¯ÁåPÉÖÃmï DV ¥ÀjªÀvÀð£É DUÀĪÀÅzÀÄ
4) ¥ÉÊgÀĪÉÃmï DPÀì¯ÉÆÃC¹mÉÃmï DV ¥ÀjªÀvÀð£É DUÀĪÀÅzÀÄ
42. ¦üãÁ¯ïUÀ¼À£ÀÄß D¯ÉÆÌà ºÁ°VAvÀ ©ü£Àß JAzÀÄ ¸ÀÄ®¨sÀªÁV ¥ÀævÉåÃQ¸À§ºÀÄzÀÄ PÁgÀt
1) D¯ÉÆÌúÁ¯ïUÀ¼ÀÄ ¸ÉÆÃrAiÀĪÀiï ¨ÉÊPÁ¨ÉÆÃð£ÉÃmï£À°è «°Ã£ÀªÁUÀĪÀŪÀÅ DzÀgÉ ¦üãÁ¯ï ºÁUÁUÀzÀÄ
2) D¯ÉÆÌúÁ¯ïUÀ¼ÀÄ ¸ÉÆÃrAiÀĪÀiï ºÉÊqÁæPÉìöÊr£À°è «°Ã£ÀªÁUÀĪÀªÀÅ DzÀgÉ ¦üãÁ¯ï ºÁUÁUÀzÀÄ
3) ¦üãÁ¯ïUÀ¼ÀÄ, ¸ÉÆÃrAiÀĪÀiï ¨ÉÊPÁ§ð£ÉÃmï£À°è «°Ã£ÀªÁUÀĪÀªÀÅ DzÀgÉ D¯ÉÆÌúÁ¯ïUÀ¼ÀÄ ºÁUÁUÀzÀÄ
4) ¦üãÁ¯ïUÀ¼ÀÄ ¸ÉÆÃrAiÀĪÀiï ºÉÊqÁæPÉìöÊr£À°è «°Ã£ÀªÁUÀĪÀªÀÅ DzÀgÉ D¯ÉÆÌúÁ¯ïUÀ¼À®è.
43. D®àçeÉÆîªÀiï C£ÀÄߪÀÅzÀÄ AiÀiÁªÀ ªÀÄzÀÄÝ ªÀÄvÀÄÛ ¥Àæ¸ÁzsÀ£À µÉqÀÆå¯ïUÉ M¼À¥ÀqÀÄvÀÛzÉ.
1) µÉqÀÆå¯ï f
2) µÉqÀÆå¯ï JZï1
3) µÉqÀÆå¯ï eÉ
4) µÉqÀÆå¯ï JPïì
235 (13 – A )
37. Anionic surfactant includes all,
EXCEPT
1) Benzalkonium chloride
2) Calcium oleate
3) Sodium lauryl sulphate
4) Sodium stearate
38. Oil soluble surfactants
1) Are efficient solubilizing agent
2) Are hydrophilic
3) Can used as emulsifier to
produce water-in-oil emulsion
4) Have high HLB values
39. The chemical composition of cell
wall of Gram-positive organism
contains all below, EXCEPT
1) Lipopolysaccharides
2) Lipoproteins
3) Peptidoglycans
4) Teichoic acids
40. An example of Gram-positive cocci
1) Clostridium
2) Neisseria meningitides
3) Pseudomonas
4) Staphylococcus aureus
41. In alcohol fermentation process
1) Pyruvate is converted into
acetone
2) Pyruvate is converted to ethanol
and carbon dioxide
3) Pyruvate is converted to lactate
4) Pyruvate is converted to
oxaloacetate
42. Phenols can be easily distinguished
from alcohols because
1) Alcohols are soluble in sodium
bicarbonate, but phenols are not
2) Alcohols are soluble in sodium
hydroxide, but phenols are not
3) Phenols are soluble in sodium
bicarbonate, but alcohols are not
4) Phenols are soluble in sodium
hydroxide, but alcohols are not
43. Alprazolam falls under which
schedule of Drugs and Cosmetic
Rules
1) Schedule G
2) Schedule H1
3) Schedule J
4) Schedule X
235 (14 – A )
44. ±ÀÆ£ÀåªÀUÀðzÀ gÁ¸ÁAiÀĤPÀ QæAiÉÄAiÀÄ zÀgÀªÀÅ
1) JgÀqÀÆ QæAiÀiÁPÁjUÀ¼À ¸ÁgÀvÉAiÀÄ ªÉÄÃ¯É CªÀ®A©¹gÀÄvÀÛzÉ
2) MAzÀÄ QæAiÀiÁPÁjAiÀÄ ¸ÁgÀvÉAiÀÄ ªÉÄÃ¯É CªÀ®A©¹gÀÄvÀÛzÉ
3) QæAiÀiÁPÁjAiÀÄ G½PÉ ¸ÁgÀvÉAiÀÄ ªÉÄÃ¯É CªÀ®A©¹gÀÄvÀÛzÉ.
4) QæAiÀiÁPÁjUÀ¼À°è ¸ÀévÀAvÀæ.
45. F ¥ÉÊQ AiÀiÁªÀÅzÀÄ ªÀiËTPÀ ªÀÄzÀÄÝ UÀjµÀ× ªÀiËTPÀ f뮨sÀåvÉ ¥ÀqÉ¢zÉ.
1) gÁ¸ÁAiÀĤPÀªÁV C¹ÜgÀ ªÀÄzÀÄÝ
2) C¢üPÀ ªÉÆzÀ® ªÀUÀðzÀ ZÀAiÀiÁ¥ÀZÀAiÀÄQæAiÉÄ ªÀÄzÀÄÝ
3) C¢üPÀ d¯ÁPÁAQë ªÀÄzÀÄÝ
4) C¢üPÀ d®«PÀµÀðPÀ DzÀgÀÆ d®«°Ã£ÀPÀ ªÀÄzÀÄÝ.
46. F ¥ÁæªÀ¸ÉÜ II ZÀAiÀiÁ¥ÀZÀAiÀÄ QæAiÉÄUÀ¼À ¥ÉÊQ AiÀiÁªÀÅzÀÄ I WÀlÖzÀ ZÀAiÀiÁ¥ÀZÀAiÀÄ QæAiÉÄUÀ¼À£ÀÄß ªÀÄÆvÀæzÀ°è ºÉÆgÀºÁPÀĪÀAvÉ ªÀiÁqÀÄvÀÛzÉ?
1) UÀÆèPÉÆgÉÆäqÉõÀ£ï
2) d®«¨sÀd£É
3) GvÀ̵ÀðuÉ
4) C¥ÀPÀµÀðuÉ
47. ¸ÁéAiÀÄvÀÛ £ÀgÀªÀÄAqÀ® ªÀåªÀ¸ÉÜUÉ ¸ÀA§A¢ü¹zÀAvÉ F PɼÀV£ÀªÀÅUÀ¼À°è AiÀiÁªÀ ºÉýPÉAiÀÄÄ ¸Àj
1) C¦ügÉAmï £ÀÆågÁ£ïUÀ¼ÀÄ ¸ÀAeÉÕUÀ¼À£ÀÄß ¹J£ïJ¸ï¤AzÀ J¥sÉPÀÖgï CAUÀUÀ½UÉ MAiÀÄÄåvÀÛzÉ.
2) ¥ÁågÁ¹A¥ÉxÀnPï £ÀÆågÁ£ïUÀ¼ÀÄ £ÉÆgɦ£É¦üæ£ï C£ÀÄß J¥sÉPÀÖgï CAUÀPÉÌ ©qÀÄUÀqÉ ªÀiÁqÀÄvÀÛªÉ.
3) ¹A¥ÀxÉnPï £ÀÆågÁ£ïUÀ¼ÀÄ C¹mÉʯïPÉÆðãï C£ÀÄß J¥sÉPÀÖgï CAUÀUÀ¼À°è ©qÀÄUÀqÉ ªÀiÁqÀÄvÀÛªÉ.
4) ¹A¥ÀxÉnPï UÁåAVèAiÀiÁ£ï£À £ÀÆågÉÆÃ¥Àæ¸ÁgÁAUÀªÀÅ C¹mÉʯï PÉÆð£ï
48. DxÉÆÃð¸ÁÖöånPï ºÉÊ¥ÉÆÃmÉ£Àë£ïUÉ PÁgÀtªÁUÀĪÀ ªÀÄzÀÄÝ
1) DªÉÆèÃr¦£ï
2) ¯ÉƸÀlð£ï
3) ¥ÁæeÉÆù£ï
4) gÁ«Ä¦æ¯ï
49. PÉÆ°£É¸ÉÖgÁ¸ï QtéUÀ¼À£ÀÄß ¤µÉâü¸ÀĪÀ MAzÀÄ OµÀ¢üAiÀÄ°è, F PɼÀV£À AiÀiÁªÀ ®PÀëtUÀ¼ÀÄ PÀAqÀħgÀÄvÀÛªÉ?
1) ±ÀĵÀÌ (Mt) ¨Á¬Ä
2) «ÄAiÉƹ¸ï
3) mÁQPÁrðAiÀiÁ
4) ªÀÄÆwæÃAiÀÄ zsÁgÀuÉ
235 (15 – A )
44. The rate of zero order reaction is
1) Depends on concentration of
both reactants
2) Depends on concentration of one
reactant
3) Depends on the residual
concentration of the reactants
4) Independent of reactants
45. Which of the following types of drugs
possess maximum oral bioavailability
1) Chemically unstable drugs
2) Drugs with high first-pass
metabolism
3) Highly hydrophilic drugs
4) Largely hydrophobic, yet soluble
in aqueous solutions
46. Which of the following phase II
metabolic reactions make phase I
metabolites readily excretable in urine
1) Glucuronidation
2) Hydrolysis
3) Oxidation
4) Reduction
47. Which of the following statement is
correct regarding to autonomic
nervous system?
1) Afferent neurons carry signals
from the CNS to the effector
organs
2) Parasympathetic neurons release
norepinephrine in the effector
organ
3) Sympathetic neurons release
acetylcholine in the effector
organs
4) The neurotransmitter at the
sympathetic ganglion is
acetylcholine
48. A drug causing orthostatic
hypotension
1) Amlodipine
2) Losartan
3) Prazosin
4) Ramipril
49. A drug which inhibits cholinesterase
enzymes shows which of the
following symptom?
1) Dry mouth
2) Miosis
3) Tachycardia
4) Urinary retention
235 (16 – A )
50. UÀ¨sÀðzsÁgÀt CªÀ¢üAiÀÄ°è gÀPÀÛzÉÆvÀÛqÀ vÀVθÀĪÀ ¸ÀªÀÄAd¸À ªÀÄzÀÄÝ. 1) C°¹ÌgÉ£ï 2) ºÉÊqÀæ®f£ï 3) gÁ«Ä¦æ¯ï 4) mÉ°ä¸Álð£ï
51. C¤® PÉÆæªÀÄmÉÆUÀæ¦ü F QæAiÀiÁ «£Áå¸ÀzÀ DzsÁjvÀ 1) C¢ü±ÉÆõÀuÉ 2) gÁ² «vÀgÀuÉ 3) UÁvÀæ §»µÀÌgÀt 4) F J®èªÀÇ
52. F ¥ÉÊQ AiÀiÁªÀ ªÀÄzÀÝ£ÀÄß ¸ÉÃj¹ ¯ÉƪÉÇqÉÆ¥ÁzÀ CAZÀÄ CqÀØ ¥ÀjuÁªÀÄUÀ¼À£ÀÄß vÀ¦à À§ºÀÄzÀÄ? (£Á¹AiÀiÁ, ºÉÊ¥ÉÆmÉ£Àë£ï, PÁrðAiÀiÁPï CgÉÊvï«ÄAiÀiÁ¸ï) 1) CªÀÄ£ïlqÉÊ£ï 2) PÁ©ðqÉÆÃ¥À 3) gÉÆæ¤gÉÆïï 4) mÉÆïÁÌ¥ÉÆ£ï
53. F PÁgÀPÀUÀ¼À ¥ÉÊQ AiÀiÁªÀÅzÀÄ ¸À¨ï¸ÁÖ¤ëAiÀiÁ¤UÁæzÀ°è qÉÆÃ¥ÁªÉÄÊ£ï£ÀÄß ©qÀÄUÀqÉ ªÀiÁqÀ®Ä G¢ÝÃ¥À£ÀUÉƽ¸ÀĪÀÅzÀÄ?
1) CªÀÄAmïqÉÊ£ï 2) ¯ÉªÉÇÃqÉÆÃ¥Á 3) ¯ÉÆgÀnr£ï 4) gÁ«Ä¦æ¯ï
54. F PɼÀV£ÀA±ÀUÀ¼ÀÄ ¥Àæw ¨ÁåQÖÃjAiÀiÁ KeÉAlÄUÀ¼À M¼À¸ÉÃ¥ÀðqÉ ªÀÄvÀÄÛ ¸ÁjÃPÀgÀtªÀ£ÀÄß ¸ÉgÉÆâà ¸ÉàöÊ£À¯ï ªÁ»AiÀÄ°è GAlÄ ªÀiÁqÀÄvÀÛªÉ. C¥ÀªÁzÀªÉAzÀgÉ
1) ªÀĢݣÀ °¦qï «°Ã£ÀvÉ
2) ªÀĢݣÀ PÀ¤µÀÖ ¥Àæw §AzsÀPÀ ¸ÁgÀvÉ
3) ªÀĢݣÀ CtÄvÀÆPÀ
4) ªÀĢݣÀ ¥ÉÆæÃn£ï §AzsÀ
55. ªÉ¹PÉAmï QªÉÆÃvÉgÀ¦ PÁgÀPÀUÀ¼ÀÄ F J¯Áè CA±ÀUÀ¼À£ÀÄß M¼ÀUÉƼÀÄîvÀÛzÉ. EzÀ£ÀÄß ºÉÆgÀvÀÄ¥Àr¹
1) qÉÆPÉÆìgÀÄ©¹£ï
2) EqÀgÀÄ©¹£ï
3) «ÄxÉÆmÉæPÉìÃmï
4) «£ïQæ¹Öãï
56. ZÀAiÀiÁ¥ÀæwPÁgÀPÀUÀ¼ÀÄ ¸ÉÊmÉÆà mÁQìPï ¥ÀjuÁªÀĪÀ£ÀÄß F ¥ÉÊQ AiÀiÁªÀÅzÀgÀ ªÀÄÆ®PÀ ªÀiÁqÀĪÀªÀÅ.
1) £ÀÆåQè¬ÄPï DªÀÄè GvÁàzÀ£ÉAiÀÄ°è ºÀĹ ¥ÀAiÀiÁðAiÀĪÁV ªÀwð¹
2) rJ£ïJ ¸ÀA±ÉèõÀuÉAiÀÄ£ÀÄß ¥Àæw §A¢ü¹ r.J£ï.J. ¥ÀævÁåªÀÄèPÀUÀ¼À £ÀqÀÄªÉ ¸ÉÃgÀĪÀ ªÀÄÆ®PÀ
3) DgïJ£ïJ ¸ÀA±ÉèõÀuÉAiÀÄ£ÀÄß ¥Àæw §A¢ü¹ - Dgï.J£ï..J ¥ÀævÁåªÀÄèPÀUÀ¼À £ÀqÀÄªÉ ¸ÉÃgÀĪÀ ªÀÄÆ®PÀ
4) ªÉÄÊPÉÆæà lÆ姯ïì GvÉÛÃf¹ ¹ÜjÃPÀj¸ÀĪÀ ªÀÄÆ®PÀ
235 (17 – A )
50. Appropriate antihypertensive
treatment choice during pregnancy
1) Aliskiren
2) Hydralazine
3) Ramipril
4) Telmisartan
51. Gas chromatography is based on
mechanism of
1) Adsorption
2) Mass distribution
3) Size exclusion
4) All of the above
52. Which of the following drug can be
added to decrease the peripheral
adverse effects (nausea, hypotension,
cardiac arrhythmias) of levapoda?
1) Amantadine
2) Carbidopa
3) Ropinirole
4) Tolcapone
53. Which of the following agent
stimulates dopamine release in the
substantianigra?
1) Amantadine
2) Levodopa
3) Loratidine
4) Ramipril
54. A1l below factors influence the
penetration and concentration of
antibacterial agents in cerbospinal
fluid, EXCEPT
1) Lipid solubility of the drug
2) Minimum inhibitory
concentration (MIC) of the drug
3) Molecular weight of the drug.
4) Protein binding of the drug
55. Vesicant chemotherapy agents
includes all the following, EXCEPT
1) Doxorubicin
2) Idarubicin
3) Methotrexate
4) Vincristine
56. Antimetabolites exert their cytotoxic
effects by which of the following?
1) Acting as false substitutions in
the production of nucleic acids
2) Inhibiting DNA synthesis by
sliding between DNA base pairs
3) Inhibiting RNA synthesis by
sliding between RNA base pairs
4) Promoting micro tubules
assembly and stabilization
235 (18 – A )
57. AiÀiÁªÀ ¥Àæw PÁAiÀÄzÀ ®¹PÉ CvÀå¢üPÀ GzÀÝzÀ ¹ÃgÀA CzsÁðAiÀÄĵÀåªÀ£ÀÄß ºÉÆA¢zÉ?
1) IgA
2) IgE
3) IgG
4) IgM
58. EAmÁæxÉPÀ° DV ¤ÃqÀ¯ÁUÀzÀ PɪÉÆxÉgÀ¦ PÁgÀPÀ 1) ¸ÉÊmÁgÁ©£ï 2) ºÉÊqÉÆæÃPÁnð¸ÉÆãï 3) «ÄxÉÆÃmÉæPÉìÃmï 4) «AQæ¹Öãï
59. ¨ÉAeÉÆÃqÀAiÀÄeÉÆqÀAiÀiÁf¦£ï «µÀPÉÌ ¥ÀævËåµÀzsÀ 1) ¥sÀÆèªÀÄeɤ¯ï 2) ¥sÉÆðPï DªÀÄè 3) J£ï-C¹mÉʯﹹÖãï 4) ¦jqÁQì£ï
60. gÀPÀÛ£Á¼ÀzÀ ªÀÄÆ®PÀ PÉÆqÀĪÀ OµÀ¢üAiÀÄ C£ÀÄ¥ÀæªÀiÁt 2 mg ªÀÄvÀÄÛ CzÉà ªÀiËTPÀ C£ÀÄ¥ÀæªÀiÁt 4 mg. F CAvÀgÀPÉÌ PÁgÀt
1) ¨ÉÃgÉ ¨ÉÃgÉ ªÀiÁUÀðUÀ¼À°è ªÀĢݣÀ fë ®¨sÀåvÉ ¨ÉÃgÉAiÀiÁVgÀÄvÀÛzÉ.
2) ¨ÉÃgÉ ¨ÉÃgÉ ªÀiÁUÀðUÀ¼À°è ªÀÄzÀÄÝ «vÀgÀuÉ ¨ÉÃgÉ ¨ÉÃgÉAiÀiÁVgÀÄvÀÛzÉ.
3) ««zsÀ ªÀiÁUÀðUÀ¼À°è ªÀĢݣÀ «¯ÉêÁj ¨ÉÃgÉAiÀiÁVgÀÄvÀÛzÉ.
4) ZÀAiÀÄQæAiÉÄAiÀÄÄ ««zsÀ ªÀiÁUÀðUÀ¼À°è ¨ÉÃgÉ ¨ÉÃgÉAiÀiÁVgÀÄvÀÛzÉ.
61. ¹Ãdgïì ¤AiÀÄAvÀætPÉÌ aQvÁì DAiÉÄÌ
1) ¯ÉÆgÁeÉ¥ÁªÀiï IV
2) ¦ü£ÉÊmÁ¬Ä£ï IV
3) «ÄqÀeÉÆïÁªÀiï IV
4) qÀAiÀiÁeÉ¥ÁªÀiï IV
62. KnæAiÀįï DgÉÊwäAiÀiÁ¸ï£À°è EPÉÆÖæPï GvÀìfð¹zÀ zÀgÀ 220 - 300/¤«ÄµÀPÉÌ EzÀÝgÉ EzÀ£ÀÄß »ÃUÉ£À߯ÁUÀĪÀÅzÀÄ.
1) mÁåQÃAiÀiÁjwäAiÀiÁ¸ï
2) DnæAiÀįï mÁåQPÁrðAiÀiÁ
3) CnæAiÀÄ¯ï ¥sÀèlgï
4) CnæAiÀÄ¯ï ¥sÉÊ©æ¯ÉõÀ£ï
63. ªÀgÀ¥sÉj£ï ¸ÉÆÃrAiÀĪÀiï JgÀqÀÄ ¸ÀªÀiÁAVUÀ¼À (Dgï ªÀÄvÀÄÛ J¸ï) gÉøɫÄPï «Ä±Àæt EªÀÅUÀ¼À C£ÀÄPÀæªÀÄ CzsÀð fëvÀUÀ¼ÀÄ
1) Dgï – 35UÀAmÉ, J¸ï - 50 UÀAmÉ
2) Dgï – 50 UÀAmÉ, J¸ï – 35 UÀAmÉ
3) Dgï – 38 UÀAmÉ, J¸ï – 47 UÀAmÉ
4) Dgï – 47 UÀAmÉ, J¸ï – 38 UÀAmÉ
64. ªÀÄÆåPÉÆøÀ¯ï gÉÆÃUÀ¤gÉÆÃzsÀPÀvÉ GAlÄ ªÀiÁqÀĪÀ EªÀÄÄå£ÉÆÃUÉÆèé£ïUÀ¼À ªÀUÀð
1) IgG
2) IgA
3) Ig M
4) Ig D
235 (19 – A )
57. Which class of antibody has the
longest serum-half life?
1) IgA
2) IgE
3) IgG
4) IgM
58. A chemotherapy agent that cannot be
administered intrathecally
1) Cytarabine
2) Hydrocortisone
3) Methotrexate
4) Vincristine
59. The antidote for benzodiazepine
poisoning is
1) Flumazenil
2) Folic acid
3) N-acetyl cysteine
4) Pyridoxine
60. A dose of an intravenous medication
is 2 mg, and the same dose of the
medication given orally to be 4 mg
The reason for this difference is due
to
1) Bioavailability of the drug by
different routes is different
2) Distribution of the drug by
different route is different
3) Elimination of the drug by
different route is different
4) Metabolism of the drug by
different route is different
61. The treatment of choice for
controlling seizures is
1) Lorazepam IV
2) Phenytoin IV
3) Midazolam IV
4) Diazepam IV
62. In Atrial arrhythmias, the ectopic rate
of discharge is 220-300/min, this is
referred as
1) Tachyarrhythmias
2) Atrial tachycardia
3) Atrial flutter
4) Atrial fibrillation
63. Warfarin sodium is a racemic mixture
of 2 isomers, R and S The respective
half life of these isomers are
1) R - 35 hours, S - 50 hours
2) R - 50 hours, S - 35 hours
3) R - 38 hours, S - 47 hours
4) R - 47 hours, S - 38 hours
64. The class of Immunoglobulins which
provides mucosal immunity is
1) IgG
2) IgA
3) Ig M
4) Ig D
235 (20 – A )
65. aQvÁì ¥ÀæAiÀÄvÀßzÀ ¥ÁæªÀ¸ÉÜAiÀÄ£ÀÄß “xÉgÁ¦ÖPï C£ÉéõÀPÀ CzsÀåAiÀÄ£À” ªÁVzÀÄÝ
1) ¥ÁæªÀ¸ÉÜ 0
2) ¥ÁæªÀ¸ÉÜ 1
3) ¥ÁæªÀ¸ÉÜ 2
4) ¥ÁæªÀ¸ÉÜ 3
66. UÁrð£É¯Á ªÁåV£Á°¸ïUÉ «gÀÄzÀÞªÁV ¤ÃqÀĪÀAvÀºÀ ¥Àæw ¸ÀÆPÀëöäfë ªÀÄzÀÄÝ
1) ¥É¤ì°£ï f
2) ¹¥ÉÆæ¥sÁèQì£ï
3) CfvÉÆæªÉÄʹ£ï
4) ªÉÄmÉÆæäqÀeÉÆïï
67. £Á£ïjãÀ¯ï QæAiÀiÁ «£Áå¸À¢AzÀ «¯Éà ªÀiÁqÀĪÀ ¥Àæw ¸ÀÆPÀëöäfë PÁgÀPÀ
1) CªÀÄAnr£ï
2) ¥Á°«ÄQì£ïì
3) ¸É®¥ÉgÀ eÉÆãï
4) PÉÆð¹Ö£ï
68. C«Ä£ÉÆÃjAiÀiÁ F PÉÆgÀvɬÄAzÀ GAmÁUÀÄvÀÛzÉ.
1) xÉÊgÁAiÀiïØ ¥ÀæZÉÆÃzÀPÀ ºÁªÉÆðãÀÄ
2) UÉÆ£ÁqÉÆÃmÉÆæ¦ü£ïì
3) ¨É¼ÀªÀtÂUÉ ºÁªÉÆð£ÀÄ
4) Cræ£ÉÆÃPÁnðPÉÆmÉÆæ¦Pï ºÁªÉÆð£ÀÄ
69. ©ÃmÁ ¯ÁåPÀÖªÀiï ¥Àæw fêÀPÀUÀ¼ÀÄ ¨ÁåQÖÃjAiÀiÁ ªÀzsÀð£ÉAiÀÄ£ÀÄß ©üwÛ UÉÆÃqÉAiÀÄ ¸ÀA±ÉèõÀuÉAiÀÄ ________AiÉÆA¢UÉ CqÀØ §AzÀÄ vÀ¦à ÀÄvÀÛzÉ.
1) mÁæ£ïì PÁ¨ÁðQì¯ÉõÀ£ï
2) mÁæ£ïìUÉèöÊPÉÆïÉõÀ£ï
3) mÁæ£Àì«ÄqÉõÀ£ï
4) mÁæ£ïì ¥É¦ÖqÉõÀ£ï
70. ¥sÉƸÉÆáªÉÄʹ£ï UÁæªÀiï ¥Á¹nªï ªÀÄvÀÄÛ UÁæªÀiï £ÉUÉnªï fëUÀ¼À ¥ÀæwAiÀiÁV ¸ÀQæAiÀĪÁVgÀ®Ä ¨ÉÃPÁzÀ PÀ¤µÀ× ¸ÁgÀvÉ
1) 100 mcg/ml
2) 125 mcg/ml
3) 150 mcg/ml
4) 175 mcg/ml
71. ²°ÃAzsÀæUÀ¼À°è ¥Àæw ²°ÃA¢üæPÁgÀPÀªÀÅ RNA/DNA ¸ÀA±ÉèõÀuÉAiÉÆA¢UÉ CrØ¥Àr¸ÀĪÀAvÀºÀzÀÄ
1) l©ð£À¥sïä
2) DA¥sÉÆmÉj¹£ï ©
3) ¥sÀÄè¸ÉÊmÉÆù£ï
4) QÃmÉÆÃPÉÆ£ÀeÉÆïï
235 (21 – A )
65. The phase of a clinical trial referred
as “Therapeutic exploratory study” is
1) Phase 0
2) Phase 1
3) Phase 2
4) Phase 3
66. The antimicrobial drug of choice
against Gardenela Vaginalis is
1) Pencillin G
2) Ciprofloxacin
3) Azithromycin
4) Metronidazole
67. The antimicrobial agent cleared by
non-renal mechanism is
1) Amantadine
2) Polymyxins
3) Celaperazone
4) Colistin
68. Amenorrhoea is due to the deficiency
of
1) Thyroid stimulating hormone
2) Gonadotrophins
3) Growth hormone
4) Adrenocorticotropic hormone
69. Beta lactum antibiotics inhibit the
bacterial growth by interfering with
__________ of cellwall synthesis
1) Transcarboxylation
2) Transglycolation
3) Transamidation
4) Transpeptidation
70. Fosfomycin is active against gram
positive and gram negative organisms
at a minimum concentration
1) 100 mcg/ml
2) 125 mcg/ml
3) 150 mcg/ml
4) 175 mcg/ml
71. The antifungal agent which interferes
with RNA/ DNA synthesis in fungi is
1) Terbinafme
2) Amphotericin B
3) Flucytosine
4) Ketoconazole
235 (22 – A )
72. CqÉ¥sÉÆ«gï r¦ªÉÇQì¯ï£ÀÄß PÁæ¤Pï ºÉ¦mÉÊn¸ï-© UÉ ¤ÃqÀĪÀAvÀºÀzÀÄ EzÀgÀ ²¥sÁgÀ¸ÀÄ ªÀiÁqÀ¯ÁzÀ ªÀAiÀĸÀÌgÀ C£ÀÄ¥ÀæªÀiÁt
1) 10 mg qd
2) 15 mg qd
3) 20 mg qd
4) 25 mg qd
73. mÉÆ¥ÉÆÃL¸ÉƪÉÄgÉøï Qté II ªÀ£ÀÄß ¥Àæw§A¢ü¸ÀĪÀ ªÀÄzÀÄÝ(Gi ¤AzÀ S ¥ÁæªÀ¸ÉÜ)
1) Ej£ÉÆÃmÉPÀ£ï
2) ¥Áå¹èmÁPÉì¯ï
3) PÉÆèÃ¥sÁgÀ©£ï
4) JmÉÆ¥ÉƸÉÊqï
74. D¯ÉÆÌúÁ¯ï£À ¥Àæ±À¸ÀÛç ¨ÁåQÖÃjAiÀiÁ £Á±ÀPÀ ¸ÁgÀvÉAiÀÄÄ ¤Ãj£ÉÆA¢UÉ _________UÁvÁæ£ÀĸÁgÀªÁV
1) 80-90%
2) 70-80%
3) 70-90%
4) 60-90%
75. ºÉÊqÉÆæd£ï ¥ÉgÁPÉìöÊr£À (VPHP) D« ¥ÁæªÀ¸ÉÜAiÀÄ°è, vÀA¥ÁzÀ ¸ÉÊj¯ÉAmï CwPÀrªÉÄ ¸ÁgÀvÉAiÀÄ°è ¸ÀQæAiÀĪÁVgÀÄvÀÛzÉ
1) 4 mg/L
2) 8 mg/L
3) 12 mg/L
4) 16 mg/L
76. rJ£ïJ ¸ÀÄgÀĽAiÀÄ ¥Àæw (¦Zï) wgÀÄ«£À UÁvÀæ
1) 30 A0
2) 32 A0
3) 34 A0
4) 36 A0
77. PɼÀV£ÀªÀÅUÀ¼À°è AiÀiÁªÀÅzÀÄ C¥ÀAiÀiÁð¥ÀÛvÉAiÀÄ£ÀÄß ¥ÀvÉÛ ªÀiÁqÀĪÀ ¥ÀjÃPÉë
1) ¯Á¸ÉUÀß ¥ÀjÃPÉë
2) ¨ÉÃAiÀÄgï ¥ÀjÃPÉë
3) ªÀiÁ°µï ¥ÀjÃPÉë
4) ¸É°é£Á¥sï ¥ÀjÃPÉë
78. F PɼÀV£ÀªÀÅUÀ¼À°è AiÀiÁªÀÅzÀÄ QÃmÉÆøï¤AzÀ ªÀÄvÀÄÛ D¯ÉÆØøï UÀ¼À£ÀÄß ¥ÀævÉåÃQ¸ÀĪÀ ¥ÀjÃPÉë
1) N¸ÀeÉÆÃ£ï ¥ÀjÃPÉë
2) ¨É£ÉrPïÖ ¥ÀjÃPÉë
3) ¸É°é£Á¥sïì ¥ÀjÃPÉë
4) ¨Ágï¥sÁAiÀiïØ÷ ¥ÀjÃPÉë
79. qÉÊCeÉÆÃn£ÉʸÉõÀ£ï QæAiÉÄAiÀÄ°è C¤°£ï ¸À°èPÉAiÀiÁzÀ £ÀAvÀgÀ GvÁàzÀ£ÉAiÀiÁUÀĪÀ GvÀà£Àß
1) ¦ü£ÉÊ¯ï ºÉÊqÁæf£ï ºÉÊqÉÆæÃPÉÆèÃgÉÊqÀÄ ®ªÀt
2) ¨ÉAfãï qÀAiÀÄeÉÆäAiÀĪÀiï ®ªÀt
3) CeÉÆà gÀAUÀÄ ®ªÀt
4) ºÉÊqÀæfÃ£ï ºÉÊqÉÆæPÉÆèÃgÉÊqÀÄ ®ªÀt
235 (23 – A )
72. The recommended adult dose of
Adefovir Dipivoxil for the treatment
of Chronic Hepatitis B is
1) 10 mg qd
2) 15 mg qd
3) 20 mg qd
4) 25 mg qd
73. The drug which inhibits the enzyme
Topoisomerase II (Gi to S phase)
1) Irinotecan
2) Paclitaxel
3) Clofarabine
4) Etoposide
74. The optimum bactericidal
concentration of alcohol is ______ by
volume in water
1) 80-90%
2) 70-80%
3) 70-90%
4) 60-90%
75. Vapour phase Hydrogen peroxide
(VPHP), a cold gaseous sterilant is
active at very low concentration of
1) 4 mg/L
2) 8 mg/L
3) 12 mg/L
4) 16 mg/L
76. The size of each turn (pitch) of DNA
helix is
1) 30 A0
2) 32 A0
3) 34 A0
4) 36 A0
77. Which of the following test is used to
identify unsaturation
1) Lassaigne test
2) Bayer’s test
3) Molisch test
4) Selwinoff’s test
78. Which of the following test
distinguishes ketose from aldose
1) Osazone test
2) Benedict’s test
3) Selwinoff’s test
4) Barfoed’s test
79. The product formed after submitting
aniline for diazotisation reaction is
1) Phenyl hydrazine hydrochloride
salt
2) Benzene diazonium salt
3) Azo dye salt
4) Hydrazine hydrochloride salt
235 (24 – A )
80. ¥ÀAiÀiÁð¥ÀÛ C°¥sÁånPï ºÉÊqÉÆæÃPÁ§ð£ïUÀ¼ÀÄ AiÀÄÄ« ±ÀÈAUÀªÀ£ÀÄß F ªÀ®AiÀÄzÀ°è ¤ÃqÀÄvÀÛzÉ
1) 150 - 200 nm
2) 200- 300 nm
3) 400 - 600 nm
4) 300 - 400 nm
81. C¤® PÉÆæêÀiÁmÉÆÃUÁæ¦üAiÀÄ°è E¯ÉPÁÖç£ÀÄ ¸ÉgÉ »rAiÀÄĪÀ ±ÉÆÃzsÀPÀªÀÅ C¢üPÀ ¸ÀAªÉâvÀªÁVgÀĪÀÅzÀÄ F UÀÄA¥ÀÄ EgÀĪÀ CtÄUÀ¼À°è
1) D¯ÉÆ̺Á¯ïì
2) CªÉÄÊ£ïì
3) ºÉÊqÉÆæPÁ§ð£ïì
4) ºÁå¯ÉÆÃd£ïì
82. F PɼÀV£ÀªÀÅUÀ¼À ¥ÉÊQ §Æ¢gÀ»vÀªÀ®èzÀ ªÁmïªÀÄ£ï ¦ü®Ögï ¥ÀvÀæ EzÀ£ÀÄß ºÉÆgÀvÀÄ¥Àr¹
1) 40
2) 41
3) 43
4) 44
83. C¤®PÉÆæªÀÄmÉÆÃUÁæ¥sï£À «ÄÃlgï GzÀÝzÀ ¸ÀÛA sÀzÀ°è, JZïEn¦ 1 cm EzÀÝgÉ n £À ¨É¯É 1) 1 2) 10 3) 100 4) 1000
84. AiÀÄÄ£ÉÊmÉqï ¸ÉÖÃmïìPÉÆÃqï D¥sï ¥ÉqÀgÀ¯ï gÉUÀÆå¯ÉõÀ£ïì (¹J¥sïDgï) ¸ÀgÀPÀÄ GvÁàzÀ£ÉAiÀÄ ¥ÀzÀÞwUÀ¼À §UÉÎ w½¸ÀĪÀÅzÀÄ EzÀÄ
1) 21 CFR 208 & 209
2) 21 CFR 208 & 210
3) 21 CFR 210 & 211
4) 21 CFR 210 & 216
85. EArAiÀÄ£ï ¥sÁ«ÄðPÉÆæAiÀiÁzÀ ªÀÄÆgÀ£Éà DªÀÈwÛ 1985gÀ°è ¥ÀæPÀlªÁ¬ÄvÀÄ JgÀqÀ£ÉAiÀÄ C¢üPÀ ¸ÉÃ¥ÀðqÉ / ¥ÀÄgÀªÀt L¦ 1985PÉÌ, EzÀÄ ¥ÀæPÀlªÁzÀ ªÀµÀð
1) 1989 2) 1991 3) 1993 4) 1995
86. 30% UÁvÀæ/UÁvÀæ D¯ÉÆÌúÁ¯ï£ÀÄß ¥ÀÆæ¥sï §®ªÁV ¥ÀjªÀwð¹zÁUÀ
1) +47.01°o/p
2) +47.50°o/p
3) -47.01°u/p
4) -47.50°u/p
87. 1% ¨ÉÆÃjPï DªÀÄèzÀ L¸ÉÆÃC¸ÁänPïzÉÆA¢UÉ gÀPÀÛzÀ ¥Áè¸ÀäUÉ ¨ÉgÉAiÀÄĪÀ zÁæªÀt vÀAiÀiÁj¸À®Ä ¨ÉÃPÁUÀĪÀ ¸ÉÆÃrAiÀÄA PÉÆèÃgÉÊqÀÄ zÁæªÀt ¸ÁgÀvÉ [1% NaCl £À WÀ¤ÃPÀgÀt ©AzÀÄ =
-0.576°C ªÀÄvÀÄÛ 1% ¨ÉÆÃjPï DªÀÄè =
-0.288°C] 1) 0.422%w/v
2) 0.402%w/v
3) 1.039%w/v
4) 0.319%w/v
235 (25 – A )
80. Saturated aliphatic hydrocarbons give
UV peak in the following region
1) 150 - 200 nm
2) 200- 300 nm
3) 400 - 600 nm
4) 300 - 400 nm
81. Gas chromatography, Electron
capture detector is highly sensitive
towards molecules having
1) Alcohols
2) Amines
3) Hydrocarbons
4) Halogens
82. All the following are ashless
whatman filter papers except
1) 40
2) 41
3) 43
4) 44
83. For a column of a meter length (Gas
chromatograph), if the HETP is 1 cm,
then “n” value is
1) 1
2) 10
3) 100
4) 1000
84. The United States Code of Federal
Regulations (CFR) which deals with
Good Manufacturing practices is
1) 21 CFR 208 & 209
2) 21 CFR 208 & 210
3) 21 CFR 210 & 211
4) 21 CFR 210 & 216
85. Third edition of Indian
Pharmacopoeia was published in the
year 1985, the second
addendum/supplement for IP 1985
was published in the year
1) 1989
2) 1991
3) 1993
4) 1995
86. Convert 30% v/v alcohol into proof
strength
1) +47.01°o/p
2) +47.50°o/p
3) -47.01°u/p
4) -47.50°u/p
87. Find the concentration of NaCl
required to make 1% solution of
Boric acid iso-osmotic with blood
plasma [Freezing point of 1% NaCl =
-0.576°C and 1% Boric Acid =
-0.288°C]
1) 0.422%w/v
2) 0.402%w/v
3) 1.039%w/v
4) 0.319%w/v
235 (26 – A )
88. ©-§UÉ f®n£ï£À L¸ÉÆà J¯ÉQÖçPï ©AzÀÄ
1) 4.7-5.3
2) 5.0-6.5
3) 4.5-5.5
4) 4.8-5.5
89. £ÉÊmÉÆæ¨ÉAfãï jÃeÉAmï C£ÀÄß EzÀgÀ C¸ÉìÃUÉ ¸ÉÃj¸À¯ÁUÀĪÀÅzÀÄ
1) vÁªÀÄæzÀ ¸À¯ÉáÃlÄ
2) CªÉÆäAiÀĪÀiï PÉÆèÃgÉÊqÀÄ
3) ºÉÊqÉÆæd£ï ¥ÉgÁPÉìöÊqÀÄ
4) ¨ÉÆÃjPï DªÀÄè
90. ªÀiÁvÉæAiÀÄ ªÉÄïÉäöÊAiÀÄ°è C¸ÀªÀĪÁV §tÚ ºÀgÀrgÀĪÀÅzÀ£ÀÄß »ÃUÉ£ÀÄߪÀgÀÄ
1) §Æè«ÄAUï
2) ¦nAUï
3) ©è¸ÀÖjAUï
4) ªÉÆnèAUï
91. ªÀiÁvÉæ gÀZÀ£ÉUÉ §¼ÀPÉ ªÀiÁqÀĪÀ ZÀgÀ© JuÉÚAiÀÄÄ F «ÄwAiÀÄ£ÀÄß «ÄÃgÀPÀÆqÀzÀÄ
1) 0.5%w/w
2) 1%w/w
3) 1.5%w/w
4) 2%w/w
92. F ¥ÉÊQ AiÀiÁªÀÅzÀÄ PÀ¤µÀ× ±ÀQÛ PÀ£ï¥sÁªÉÄÃð±À£ï (gÀZÀ£Á PÀæªÀÄ)?
1) eÁUÀwPÀ «Ä¤ªÀiÁ PÀ£ï¥sÁªÉÄÃðµÀ£ï (gÀZÀ£ÁPÀæªÀÄ)
2) ¸ÀܽÃAiÀÄ «Ä¤ªÀiÁ PÀ£ï¥sÁªÉÄÃðµÀ£ï (gÀZÀ£ÁPÀæªÀÄ)
3) eÉÊ«QæAiÉÄ PÀ£ï¥sÁªÉÄÃðµÀ£ï (gÀZÀ£ÁPÀæªÀÄ)
4) F ªÉÄð£À J®èªÀÇ
93. ¥ÉÊgÉÆÃd¤ß£À CvÀåAvÀ ¸ÀÄ¥ÀÛgÀÆ¥À«gÀĪÀÅzÀÄ E°è
1) UÁæªÀiï ¥Á¹nªï ¨ÁåQÖÃjAiÀiÁ
2) UÁæªÀiï £ÉUÉnªï ¨ÁåQÖÃjAiÀiÁ
3) ²°ÃAzsÀæ
4) ªÉÊgÀ¸ï
94. HLB ¨É¯É8-18gÀ £ÀqÀÄªÉ EgÀĪÀ ¸À¥sÁåðPÉÖAmï G¥ÀAiÀÄÄPÀÛªÁUÀĪÀÅzÀÄ »ÃUÉ E°è 1) ªÀiÁdðPÀUÀ¼ÀÄ 2) vÉêÀPÁgÀPÀ 3) £ÉÆgÉ ¥ÀæwgÉÆÃzsÀPÀ 4) ¤Ãj£À°è JªÀÄ°ì¥sÉÊAiÀÄgï£À°è£À JuÉÚ
95. D - ¨É¯É ªÀÄvÀÄÛ F0 ¨É¯É ¥ÀzÀPÀæªÀĪÀ£ÀÄß F §UÉAiÀÄ ¸ÉÖj¯ÉʸÉõÀ£ï C£ÀÄß ¥ÉÃgÉAmïgÀ¯ï GvÀà£ÀßUÀ½UÉ §¼À¸À¯ÁUÀĪÀÅzÀÄ. 1) C¤°ÃAiÀÄ ¸ÀÖj¯ÉÖöʸÉõÀ£ï 2) DmÉÆæÃPÉèêï£À°è ©¹AiÀiÁUÀÄ«PÉ 3) ±ÉÆÃzsÀ£É 4) nAqÀ°ÃPÀgÀt
235 (27 – A )
88. The isoelectric point of Type B
gelatin is
1) 4.7-5.3
2) 5.0-6.5
3) 4.5-5.5
4) 4.8-5.5
89. Nitrobenzene reagent is added in the
assay of
1) Copper sulphate
2) Ammonium Chloride
3) Hydrogen Peroxide
4) Boric acid
90. The unequal distribution of colour on
tablet surface is known as
1) Blooming
2) Pitting
3) Blistering
4) Mottling
91. The amount of lubricants used in a
tablet formulations should not exceed
1) 0.5%w/w
2) 1%w/w
3) 1.5%w/w
4) 2%w/w
92. Which among the following is the
lowest energy conformation
1) Global minima conformation
2) Local minima conformation
3) Bioactive conformation
4) All the above
93. The most potent form of pyrogens are
found in
1) Gram positive bacteria
2) Gram negative bacteria
3) Fungi
4) Virus
94. A surfactant having an HLB value
between 8 and 18 is likely to be
useful for
1) Detergents
2) Wetting agent
3) Anti foaming agent
4) Oil in water emulsifier
95. D-value and F0 value terminology is
associated with the following type of
sterilization process of parenteral
products
1) Gaseous sterilization
2) Heating in autoclave
3) Filtration
4) Tyndallisation
235 (28 – A )
96. ¸ÀtÚ £ÀAiÀĪÁzÀ PÀtUÀ¼À vÀÄAvÀÄgÀÄ ªÀiÁqÀ®Ä OµÀ¢üAiÀÄ zÁæªÀtUÀ¼ÀÄ CxÀªÁ ¤®A§£ÉUÀ¼À°è C¢üPÀ C£ÀÄ¥ÀæªÀiÁt ªÀÄzÀÄÝ ¤ÃqÀ®Ä §¼ÀPÉ ªÀiÁqÀĪÀ ¸ÁzsÀ£À
1) ¥sÉgÀÆå¯ï
2) DPÀÄÑAiÉÄÃlgï
3) «ÄÃlgïØ KgÉÆøÁ¯ïUÀ¼ÀÄ
4) £É§Ä¯ÉʸÀgï
97. ªÀiÁvÉæ ¯ÉÃ¥À£À ¥ÀæQæAiÉÄAiÀÄ°è ¯ÉÃ¥À£ÀzÀ C¸ÀªÀÄ¥ÀðPÀ ºÀgÀqÀÄ«PÉ MtV¸ÀĪÀ ªÉÆzÀ®Ä DzÀgÉ F ¥ÀjuÁªÀÄ DUÀÄvÀÛzÉ.
1) DgÉÃAeï ¦Ã¯ï ¥ÀjuÁªÀÄ
2) §Æè«ÄAUï ¥ÀjuÁªÀÄ
3) ©è¸ÀÖjAUï ¥ÀjuÁªÀÄ
4) PÀĽ©Ã¼ÀĪÀ ¥ÀjuÁªÀÄ
98. ¥ÀÄr ªÀiÁzÀjAiÀÄ£ÀÄß ‘¸ÁzsÁgÀt £ÀÄtÄ¥ÀÄ’ JAzÀÄ ºÉüÀ¨ÉÃPÁzÀgÉ D ¥ÀÄrAiÀÄ J¯Áè PÀtUÀ¼ÀÄ EzÀgÀ ªÀÄÆ®PÀ ºÁAiÀĨÉÃPÀÄ.
1) dgÀr ¸ÀASÉå 10
2) dgÀr ¸ÀASÉå 20
3) dgÀr ¸ÀASÉå 22
4) dgÀr ¸ÀASÉå 40
99. ¥ÀgÁ¸ÀgÀt ºÉÆgÉAiÀÄ£ÀÄß PÀgÀĽUÉ
¸ÀA§A¢ü¹zÀAvÉ ¤ÃgÀ£ÀÄß C¢üPÀ
¥ÀæªÀiÁtzÀ°è »Ãj ºÉZÀѼÀUÉƽ¹,
¥Éj¸ÁÖ°ì¸ï£ÀÄß ¥ÀæZÉÆâ¸ÀĪÀ PÁgÀPÀUÀ¼ÀÄ
1) ¹ÖªÀÄÄå¯ÉAmïì
2) §¯ïÌ gÉÃZÀPÀUÀ¼ÀÄ
3) ZÀgÀ©UÀ¼ÀÄ
4) ¸À¯ÉÊ£ï PÉxÀnðPïì
100. zÀÄåw¹ÜgÀvÁ CzsÀåAiÀÄ£ÀUÀ¼À°è OµÀ¢üÃAiÀÄ
GvÀà£ÀߪÀÅ MmÁÖgÉ ¨É¼ÀQUÉ MrØPÉÆAqÀÄ
ªÀÄvÀÄÛ ¸ÀªÀÄUÀæªÁV MrØPÉƼÀÄîªÀÅzÀÄ
C£ÀÄPÀæªÀĪÁV EzÀQÌAvÀ PÀrªÉÄ EgÀ¨ÁgÀzÀÄ
1) 1200000 Lux WÀAmÉUÀ¼ÀÄ & 200
ªÁmï WÀAmÉUÀ¼ÀÄ/m3
2) 1200000 Lux WÀAmÉUÀ¼ÀÄ & 300
ªÁmï WÀAmÉUÀ¼ÀÄ/m3
3) 1000000 Lux WÀAmÉUÀ¼ÀÄ & 200
ªÁmï WÀAmÉUÀ¼ÀÄ/m3
4) 1000000 Lux WÀAmÉUÀ¼ÀÄ & 300
ªÁmï WÀAmÉUÀ¼ÀÄ/m3
235 (29 – A )
96. The device used to generate a mist of
fine particles from a drug solution or
suspension to deliver high doses of
drug is
1) Ferrule
2) Actuator
3) Metered aerosols
4) Nebulizer
97. In the tablet coating process,
inadequate spreading of the coating
solution before drying causes
1) Orange peel effect
2) Blooming effect
3) Blistering effect
4) Cratering effect
98. A powder sample is said to
‘‘Moderately fine” if all the particles
of the powder pass through
1) Sieve No. 10
2) Sieve No. 20
3) Sieve No. 22
4) Sieve No. 40
99. The agents which increase the
osmotic load of intestine by absorbing
large quantities of water and thereby
stimulate peristalsis is
1) Stimulants
2) Bulk purgatives
3) Lubricants
4) Saline cathartics
100. During photostability studies of a
pharmaceutical product, the overall
light exposure and integrated
exposure should be NOT LESS
THAN (respectively)
1) 1200000 Lux hours & 200 watt
hours/m3
2) 1200000 Lux hours & 300 watt
hours/m3
3) 1000000 Lux hours & 200 watt
hours/m3
4) 1000000 Lux hours & 300 watt
hours/m3
235 (32 – A )
DO NOT OPEN THIS QUESTION BOOKLET UNTIL YOU ARE ASKED TO DO SO
Question Booklet Series
QUESTION BOOKLET
SPECIFIC PAPER
(PAPER II)
Time Allowed : 2 Hours Maximum Marks : 200
INSTRUCTIONS
1. Immediately after the commencement of the Examination, before writing the Question Booklet
Series in the OMR sheet, you should check that this Question Booklet does NOT have any unprinted
or torn or missing pages or questions etc. If so, get it replaced by a complete ‘Question Booklet’ of the
available series.
2. Write and encode clearly the Question Booklet Series A, B, C or D, Subject Code and
Register Number in the appropriate space provided for that purpose in the OMR Answer
Sheet. Also ensure that candidate’s signature and Invigilator’s signature columns are
properly filled in. Please note that it is candidate’s responsibility to fill in and encode
these particulars and any omission/discrepancy will render the OMR Answer Sheet liable
for Rejection.
3. You have to enter your Register Number in the
Question Booklet in the box provided alongside.
DO NOT write anything else on the Question Booklet.
4. This Question Booklet contains 100 questions. Each question contains four responses (answers).
Select the response which you want to mark on the Answer Sheet. In case you feel that there is more
than one correct response, mark the response which you consider the most appropriate. In any case,
choose ONLY ONE RESPONSE for each question.
5. All the responses should be marked ONLY on the separate Answer Sheet provided and ONLY in
Black or Blue Ball Point Pen. See detailed instructions in the OMR Answer Sheet.
6. All questions carry equal marks. Attempt all questions. Every question for which wrong answer has been given by the candidate, 1/4th (0.25) of the marks assigned for that question will be deducted.
7. Sheets for rough work are appended in the Question Booklet at the end. You should not make any
marking on any other part of the Question Booklet.
8. Immediately after the final bell indicating the conclusion of the examination, stop making any
further markings in the Answer Sheet. Be seated till the Answer Sheets are collected and accounted
for by the Invigilator.
9. Questions are printed both in Kannada and English. If any confusion arises in the
Kannada Version, please refer to the English Version of the questions. Please note that in
case of any confusion the English Version of the Question Booklet is final.
WÜÊÜá¯Ô : ÓÜãaÜ®æWÜÙÜ PܮܰvÜ BÊÜ꣤¿áá D ±ÜÅÍæ° ±ÜâÔ¤Pæ¿á ÊÜááí»ÝWܨÜÈÉ ÊÜáá©ÅÓÜƳqr æ.
A SUBJECT CODE : 235
Register Number
Use of Mobile Phones, Calculators and other Electronic/Communication gadgets of any kind
is prohibited inside the Examination venue.